Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment
19 October 2023
11:00 AM – 12:00 PM ET
Presented by the OATP Biomarkers Working Group
Sponsored by the Translational and ADME Sciences Leadership Group
Bridget Morse, Eli Lilly
Ryota Kikuchi, AbbVie
Drug-drug interactions (DDIs) involving hepatic organic anion transporting polypeptides 1B1/1B3 (OATP1B) can be substantial, however, challenges remain for predicting interaction risk. Emerging evidence suggests that endogenous biomarkers, particularly coproporphyrin-I (CP-I), can be used to assess in vivo OATP1B activity. The IQ OATP1B Biomarkers Working Group was aimed primarily at assessing CP-I as a biomarker for informing OATP1B DDI risk, through the following:
- Compiling available OATP1B biomarker data, clinical OATP1B DDI data, and in vitro data against enzymes and transporters relevant for the disposition of OATP1B substrates
- Addressing OATP1B contribution to observed OATP1B substrate DDIs
- Evaluating the use of CP-I for refining risk of clinically relevant OATP1B-mediated DDIs
- Identifying changes in CP-I exposure associated with OATP1B-mediated DDIs, that may be used to prioritize, delay or replace clinical DDI studies
- Assessing the relationship between CP-I change and current static models
- Providing recommendations for the collection and interpretation of CP-I in clinical studies, including a decision tree for guiding DDI risk assessment
During this webinar the working group will present this work leading to the conclusion that clinical measurement of CP-I is recommended to inform OATP1B inhibition potential.
This webinar is open to the public. Membership in the IQ Consortium is not required for registration.